Optimizerx Stock News

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sapiens (SPNS) delivered earnings and revenue surprises of 14.81% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCHESTER, Mich., April 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay o

ROCHESTER, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay o

I like to read articles by people who aren't just bullish -- they've bought shares.

OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the

OptimizeRx Corporation (NASDAQ:OPRX) concluded the trading at $45.19 on Friday, February 25 with a rise of 5.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $42.97 and 5Y monthly beta was reading 0.57 with its price kept floating in the range … OptimizeRx Corporation (OPRX) Rises From The Low: Could It Be A Catbird Seat? Read More »

OPRX earnings call for the period ending December 31, 2021.

OPRX earnings call for the period ending December 31, 2021.

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?